10:16 AM EDT, 03/11/2024 (MT Newswires) -- NetraMark Holdings Inc. ( AINMF ) , a generative AI software player in clinical trial analytics, on Monday announced the presentation of new data showing the ability of its NetraAI clinical trial solution to untangle the web of factors contributing to Parkinson's Disease (PD), offering insights applicable to other neurodegenerative disorders, including Alzheiimer's Disease.

The application of NetraAI to a dataset of 588 individuals provided by the Michael J. Fox Foundation identified multiple markers associated with PD pathogenesis, including several that are closely linked to the immune system and immune responses. The data was presented in a poster at AD/PDTM 2024, which took place March 5-9 in Lisbon, Portugal.